在T4鼻咽癌调强放疗中优先保证肿瘤大体体积足够剂量而非正常组织保护
该单中心队列纳入2005年7月至2010年12月间确诊并接受调强放疗的T4鼻咽癌患者,按第7版AJCC分期重新分期。结果显示脑干、视神经、视交叉、颞叶和脊髓等中枢神经系统危及器官的平均剂量(Dmax、D1%、D2%、D1cc)超过RTOG0225指南,但随访期间除13%患者出现颞叶坏死外未见临床毒性。作者认为在超过多数中枢神经系统危及器官约束标准的同时最大化肿瘤大体体积剂量覆盖是可行的,局部控制理想且未明显增加颅脑毒性。
要点
- T4鼻咽癌调强放疗中中枢神经系统危及器官平均剂量超过RTOG0225标准。
- 随访期间除13%患者出现颞叶坏死外未见其他临床毒性。
- 作者认为最大化肿瘤大体体积剂量覆盖同时超过多数中枢神经系统约束是可行的。
核心结论
- 作者回顾性分析认为,在T4鼻咽癌调强放疗中最大化肿瘤大体体积剂量覆盖同时超过多数中枢神经系统危及器官约束标准是可行的,局部控制理想且未明显增加颅脑毒性。
研究设计与样本
- 单中心队列研究,纳入2005年7月至2010年12月间确诊并接受调强放疗的T4鼻咽癌患者,所有患者按第7版AJCC分期重新分类。
主要发现
- 脑干、视神经、视交叉、颞叶和脊髓等中枢神经系统危及器官的平均Dmax、D1%、D2%和D1cc剂量超过RTOG0225发布的指南标准。
- 随访期间除13%患者出现颞叶坏死外,未见其他临床毒性。
关键数值与推荐
- 脑干、视神经、视交叉、颞叶和脊髓等中枢神经系统危及器官的平均Dmax、D1%、D2%和D1cc剂量超过RTOG0225指南标准。
- 随访期间13%患者出现颞叶坏死,未见其他临床毒性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In intensity-modulated radiation therapy (IMRT) for nasopharyngeal carcinoma (NPC), priority is often given minimize dose to the critical organs at risk (OARs) to avoid potential morbid sequelae. However, in T4 NPC, dosimetric inadequacy enforced by dose constraints on OARs may significantly impact tumor control. METHODS: This was a single-institute cohort that patients diagnosed between July 2005 and December 2010 with T4 NPC treated with IMRT. All patients were re-classification according to the 7th-AJCC stage. RESULTS: Overall, the average doses such as Dmax , D1% , D2% and D1cc for various Central nervous system (CNS) OARs including brainstem, optic nerve, chiasm, temporal lobes and spinal cord were found to exceed published guidelines as RTOG0225. However, no clinical toxicities were seen during the follow-up period except for 13% patients with temporal lobe necrosis. CONCLUSION: Our retrospective review showed that its feasible to maximize gross tumor volume dose coverage while exceeding most CNS OAR constraint standards, with ideal local control and no obvious increase of craniocerebral toxicity.
引用
- Chen Y, Zhang Q, Lu T, et al. Prioritizing sufficient dose to gross tumor volume over normal tissue sparing in intensity-modulated radiotherapy treatment of T4 nasopharyngeal carcinoma. Head Neck. 2023. PMID: 36856128. doi:10.1002/hed.27315
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。